High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature

Bhaskar C. Kolla, Nurul A.A. Halim, Qing Cao, Zohar Sachs, Erica Warlick, Daniel Weisdorf, Aloysius Y.L. Ho, Wong G. Chuan, Zhentang Lao, Fiona He

Research output: Contribution to journalArticlepeer-review

Abstract

Following the 2017 European LeukemiaNet (ELN) guidelines, we changed our practice from using high-dose cytarabine (HIDAC-3 g/m2 q12h-D1,3,5) to intermediate-dose cytarabine (IDAC-1·5 g/m2 q12h-D1,3,5/D1–3) for consolidation in young(<60 years) favourable-risk acute myeloid leukaemia (AML) patients. We assessed the clinical impact of this practice change. Of 80 patients, 51 received HIDAC prior to the protocol change, and subsequently, 29 received IDAC. The three-year risk of relapse was significantly higher with IDAC [61%; 95% confidence interval (CI) 40–82] compared with HIDAC (22%; 10–34), P < 0·01. Our findings suggest HIDAC, rather than IDAC, is the preferred dose for single-agent cytarabine consolidation in young, favourable-risk AML following 7+3 induction.

Original languageEnglish (US)
Pages (from-to)140-144
Number of pages5
JournalBritish journal of haematology
Volume194
Issue number1
DOIs
StatePublished - Jul 2021

Bibliographical note

Funding Information:
None of the authors received funding support for the conduct of this study. Support received outside of this study: DW received research support from FATE therapeutics and Incyte; ZL received NMRC research training fellowship, speaker fees from Astellas and Amgen, honoraria from Astellas, Amgen and Novartis; ZS received research reagents from Jazz pharmaceuticals, research funds and reagents from Stemline therapeutics; FH received consultant fees from Abbvie and Magenta therapeutics.

Publisher Copyright:
© 2021 British Society for Haematology and John Wiley & Sons Ltd

Keywords

  • acute leukaemia
  • chemotherapy
  • consolidation

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature'. Together they form a unique fingerprint.

Cite this